Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Bolt Biotherapeutics (BOLT) Return on Sales (2020 - 2025)

Bolt Biotherapeutics' Return on Sales history spans 6 years, with the latest figure at 3.33% for Q3 2025.

  • For Q3 2025, Return on Sales rose 997.0% year-over-year to 3.33%; the TTM value through Sep 2025 reached 8.25%, down 111.0%, while the annual FY2024 figure was 8.82%, 3.0% down from the prior year.
  • Return on Sales for Q3 2025 was 3.33% at Bolt Biotherapeutics, up from 4.77% in the prior quarter.
  • Across five years, Return on Sales topped out at 2.94% in Q1 2024 and bottomed at 876.42% in Q1 2021.
  • The 5-year median for Return on Sales is 11.45% (2023), against an average of 62.48%.
  • The largest annual shift saw Return on Sales crashed -82378bps in 2021 before it skyrocketed 84729bps in 2022.
  • A 5-year view of Return on Sales shows it stood at 53.46% in 2021, then skyrocketed by 73bps to 14.17% in 2022, then soared by 40bps to 8.57% in 2023, then fell by -3bps to 8.82% in 2024, then skyrocketed by 62bps to 3.33% in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Return on Sales are 3.33% (Q3 2025), 4.77% (Q2 2025), and 9.05% (Q1 2025).